Strategies for management of patients with, or at risk for, medication-related osteonecrosis of
the jaws (MRONJ)–formerly referred to as bisphosphonate-related osteonecrosis of the jaws …

Medication-related osteonecrosis of the jaw (MRONJ) is a potentially severe adverse event
affecting patients with cancer and patients with osteoporosis who have been treated with …

It is well established that alterations in phosphate metabolism have a profound effect on
hard and soft tissues of the oral cavity. The present-day clinical form of osteonecrosis of the …

Medication-related osteonecrosis of the jaw (MRONJ) is a potentially severe, debilitating
condition affecting patients with cancer and patients with osteoporosis who have been …

Medication‐related osteonecrosis of the jaw (MRONJ) is a rare but serious adverse effect of
antiresorptive medications administered for control of osseous malignancy, osteoporosis, or …

Medication-related osteonecrosis of the jaw (MRONJ) is primarily associated with
administering antiresorptive or antiangiogenic drugs. Despite significant research on …

Introduction Osteonecrosis of the jaw (ONJ) is an adverse event that requires association of
both systemic risk factors, such as powerful anti-resorptives (pARs; eg zoledronic acid …

The effect of anti-resorptive drug (ARD) usage among patients with successful dental
implant osseointegration is controversial. This study showed an increased risk of implant …

Abstract Objective Angiogenesis inhibitors (AgI) are commonly used in combination
chemotherapy protocols to treat cancer, and have been linked to osteonecrosis of the jaw …

Background The aim of this study is to compare the effects of icariin and teriparatide on the
treatment of medication‐related osteonecrosis of the jaw (MRONJ) using a rat model …